Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1

Journal of Biological Chemistry

Volumn 290, Issue 7, 2015, Pages 4022-4037

  Steeland, Sophie ^a,b   Puimège, Leen ^a,b   Vandenbroucke, Roosmarijn E ^a,b   Van Hauwermeiren, Filip ^a,b   Haustraete, Jurgen ^b   Devoogdt, Nick ^c   Hulpiau, Paco ^a,b   Leroux Roels, Geert ^d   Laukens, Debby ^d   Meuleman, Philip ^d   De Vos, Martine ^d   Libert, Claude ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; BIOLOGY;

AUTOIMMUNE DISEASE; EX-VIVO; HUMAN TUMORS; IMMUNOMODULATORY; IN-VITRO; IN-VIVO; NANOBODY; SINGLE-DOMAIN ANTIBODIES;

DISEASE CONTROL;

INTERLEUKIN 6; LYMPHOTOXIN; NANOBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1 ANTIBODY; UNCLASSIFIED DRUG; CYTOKINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; EPITOPE MAPPING; EX VIVO STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; HEPATITIS; HUMAN; HUMAN TISSUE; IC50; IL8 GENE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR CLONING; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; TNF GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; COLON; CROHN DISEASE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; INFLAMMATION; LIVER; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PROTEIN CONFORMATION; SCID MOUSE; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; COLON; CROHN DISEASE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HUMANS; INFLAMMATION; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; SINGLE-DOMAIN ANTIBODIES; SURFACE PLASMON RESONANCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922775279     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.617787     Document Type: Article

References (84)

1. Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003) Tumor necrosis factor signaling. Cell Death Differ. 10, 45-65
2. MacEwan, D. J. (2002) TNF ligands and receptors-a matter of life and death. Br. J. Pharmacol. 135, 855-875
3. Van Hauwermeiren, F., Vandenbroucke, R. E., and Libert, C. (2011) Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 22, 311-319
4. Aggarwal, B. B. (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745-756
5. Faustman, D., and Davis, M. (2010) TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discov. 9, 482-493
6. Verweij, C. L. (2009) Predicting the future of anti-tumor necrosis factor therapy. Arthritis Res. Ther. 11, 115
7. Esters, N., Vermeire, S., Joossens, S., Noman, M., Louis, E., Belaiche, J., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., Poulain, D., Bossuyt, X., Rutgeerts, P., and Belgian Group of Infliximab Expanded Access Program in Crohn's, Disease. (2002) Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am. J. Gastroenterol. 97, 1458-1462
8. Kim, S. Y., and Solomon, D. H. (2010) Tumor necrosis factor blockade and the risk of viral infection. Nat. Rev. Rheumatol. 6, 165-174
9. Cleynen, I., and Vermeire, S. (2012) Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat. Rev. Gastroenterol. Hepatol. 9, 496-503
10. Fellermann, K. (2013) Adverse events of tumor necrosis factor inhibitors. Dig. Dis. 31, 374-378
11. Kary, S., Worm, M., Audring, H., Huscher, D., Renelt, M., Sörensen, H., Ständer, E., Maass, U., Lee, H., Sterry, W., and Burmester, G. R. (2006) New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor αantagonists. Ann. Rheum. Dis. 65, 405-407
12. Vermeire, S., Noman, M., Van Assche, G., Baert, F., Van Steen, K., Esters, N., Joossens, S., Bossuyt, X., and Rutgeerts, P. (2003) Autoimmunity associated with anti-tumor necrosis factor αtreatment in Crohn's disease: a prospective cohort study. Gastroenterology 125, 32-39
13. Katikireddi, V. S., Whittle, S. L., and Hill, C. L. (2010) Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. Int. J. Rheum. Dis. 13, 12-26
14. Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., Willerson, J. T., and Anti-TNF Therapy Against Congestive Heart Failure Investigators (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-β, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133-3140
15. Cohen, M., Baldin, B., Thomas, P., and Lebrun, C. (2012) Neurological adverse events under anti-TNFα therapy. Revue Neurologique 168, 33-39
16. Atzeni, F., Talotta, R., Salaffi, F., Cassinotti, A., Varisco, V., Battellino, M., Ardizzone, S., Pace, F., and Sarzi-Puttini, P. (2013) Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun. Rev. 12, 703-708
17. Rosenblum, H., and Amital, H. (2011) Anti-TNF therapy: safety aspects of taking the risk. Autoimmun. Rev. 10, 563-568
18. Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B., Bendahman, N., and Hamers, R. (1993) Naturally occurring antibodies devoid of light chains. Nature 363, 446-448
19. Muyldermans, S. (2013) Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775-797
20. Siontorou, C. G. (2013) Nanobodies as novel agents for disease diagnosis and therapy. Int. J. Nanomedicine 8, 4215-4227
21. Els Conrath, K., Lauwereys, M., Wyns, L., and Muyldermans, S. (2001) Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J. Biol. Chem. 276, 7346-7350
22. Saerens, D., Kinne, J., Bosmans, E., Wernery, U., Muyldermans, S., and Conrath, K. (2004) Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J. Biol. Chem. 279, 51965-51972
23. Conrath, K. E., Lauwereys, M., Galleni, M., Matagne, A., Frère, J. M., Kinne, J., Wyns, L., and Muyldermans, S. (2001)β-Lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob. Agents Chemother. 45, 2807-2812
24. Skerra, A., and Plückthun, A. (1988) Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240, 1038-1041
25. Ablynx (September 7, 2007) WO Patent 2008/028977 A2
26. Schoonooghe, S., Leoen, J., and Haustraete, J. (2012) Production of antibody derivatives in the methylotrophic yeast Pichia pastoris. Methods Mol. Biol. 907, 325-340
27. Sali, A., and Blundell, T. L. (1993) Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815
28. Larsson, P., Wallner, B., Lindahl, E., and Elofsson, A. (2008) Using multiple templates to improve quality of homology models in automated homology modeling. Protein Sci. 17, 990-1002
29. Lovell, S. C., Davis, I. W., Arendall, W. B., 3rd, de Bakker, P. I., Word, J. M., Prisant, M. G., Richardson, J. S., and Richardson, D. C. (2003) Structure validation by C-geometry: φ,ψ and C-deviation. Proteins 50, 437-450
30. Kozakov, D., Beglov, D., Bohnuud, T., Mottarella, S. E., Xia, B., Hall, D. R., and Vajda, S. (2013) How good is automated protein docking? Proteins 81, 2159-2166
31. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., and Speleman, F. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034
32. Meuleman, P., and Leroux-Roels, G. (2008) The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res. 80, 231-238
33. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., and Speleman, F. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034
34. Tateno, C., Yoshizane, Y., Saito, N., Kataoka, M., Utoh, R., Yamasaki, C., Tachibana, A., Soeno, Y., Asahina, K., Hino, H., Asahara, T., Yokoi, T., Furukawa, T., and Yoshizato, K. (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 165, 901-912
35. Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R., and Muyldermans, S. (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414, 521-526
36. Desmyter, A., Transue, T. R., Ghahroudi, M. A., Thi, M. H., Poortmans, F., Hamers, R., Muyldermans, S., and Wyns, L. (1996) Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. 3, 803-811
37. Arnold, K., Bordoli, L., Kopp, J., and Schwede, T. (2006) The SWISSMODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22, 195-201
38. Wajant, H., and Scheurich, P. (2011) TNFR1-induced activation of the classical NF-κB pathway. FEBS J. 278, 862-876
39. Chuang, V. T., Maruyama T., and Otagiri, M. (2009) Updates on contemporary protein binding techniques. Drug Metab. Pharmacokinet. 24, 358-364
40. Cregg, J. M., Cereghino, J. L., Shi, J., and Higgins, D. R. (2000) Recombinant protein expression in Pichia pastoris. Mol. Biotechnol. 16, 23-52
41. Cortez-Retamozo, V., Lauwereys, M., Hassanzadeh Gh, G., Gobert, M., Conrath, K., Muyldermans, S., De Baetselier, P., and Revets, H. (2002) Efficient tumor targeting by single-domain antibody fragments of camels. Int. J. Cancer 98, 456-462
42. Heyninck, K., Wullaert A., and Beyaert, R. (2003) Nuclear factor-βB plays a central role in tumour necrosis factor-mediated liver disease. Biochem. Pharmacol. 66, 1409-1415
43. Ben-Horin, S., and Chowers, Y. (2011) Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment. Pharmacol. Ther. 33, 987-995
44. Panés, J., and Ghosh, S. (2007) The classics in perspective. Gut 56, 1184-1186
45. Schabert, V. F., Watson, C., Joseph, G. J., Iversen, P., Burudpakdee, C., and Harrison, D. J. (2013) Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J. Manag. Care Pharm. 19, 621-630
46. Banner, D. W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H. J., Broger, C., Loetscher, H., and Lesslauer, W. (1993) Crystal structure of the soluble human 55 kdTNFreceptor-humanTNFα complex: implications forTNF receptor activation. Cell 73, 431-445
47. Coppieters, K., Dreier, T., Silence, K., de Haard, H., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., Van de Wiele, C., Staelens, L., Hostens, J., Revets, H., Remaut, E., Elewaut, D., and Rottiers, P. (2006) Formatted anti-tumor necrosis factor αVHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 54, 1856-1866
48. Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., and Damico, L. A. (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277, 35035-35043
49. Dixon, F. J., Maurer, P. H., and Deichmiller, M. P. (1953) Half-lives of homologous serum albumins in several species. Proc. Soc. Exp. Biol. Med. 83, 287-288
50. Liu, M., Huang, Y., Hu, L., Liu, G., Hu, X., Liu, D., and Yang, X. (2012) Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. BMC Biotechnol. 12, 68
51. Wunder, A., Müller-Ladner, U., Stelzer, E. H., Funk, J., Neumann, E., Stehle, G., Pap, T., Sinn, H., Gay, S., and Fiehn, C. (2003) Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J. Immunol. 170, 4793-4801
52. Deng, G. M., Liu, L., Kyttaris, V. C., and Tsokos, G. C. (2010) Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway. J. Immunol. 184, 7154-7161
53. Milatovich, A., Song, K., Heller, R. A., and Francke, U. (1991) Tumor necrosis factor receptor genes, TNFR1 and TNFR2, on human chromosomes 12 and 1. Somat. Cell Mol. Genet. 17, 519-523
54. Tada, Y., Ho, A., Koarada, S., Morito, F., Ushiyama, O., Suzuki, N., Kikuchi, Y., Ohta, A., Mak, T. W., and Nagasawa, K. (2001) Collagen-induced arthritis in TNF receptor-1-deficient mice: TNF receptor-2 can modulate arthritis in the absence of TNF receptor-1. Clin. Immunol. 99, 325-333
55. Blüml, S., Binder, N. B., Niederreiter, B., Polzer, K., Hayer, S., Tauber, S., Schett, G., Scheinecker, C., Kollias, G., Selzer, E., Bilban, M., Smolen, J. S., Superti-Furga, G., and Redlich, K. (2010) Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum. 62, 1608-1619
56. Abu-Amer, Y., Erdmann, J., Alexopoulou, L., Kollias, G., Ross, F. P., and Teitelbaum, S. L. (2000) Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J. Biol. Chem. 275, 27307-27310
57. Aggarwal, B. B. (2014) Balancing TNFR1 and TNFR2 jointly for joint inflammation. Arthritis Rheumatol. 66, 2657-2660
58. McCann, F. E., Perocheau, D. P., Ruspi, G., Blazek, K., Davies, M. L., Feldmann, M., Dean, J. L., Stoop, A. A., and Williams, R. O. (2014) Selective TNFR1 blockade is anti-inflammatory and reveals an immunoregulatory role for TNFR2. Arthritis Rheumatol. 66, 2728-2738
59. Housley, W. J., Adams, C. O., Nichols, F. C., Puddington, L., Lingenheld, E. G., Zhu, L., Rajan, T. V., and Clark, R. B. (2011) Natural but not inducible regulatory T cells require TNF-κ signaling for in vivo function. J. Immunol. 186, 6779-6787
60. Chen, X., Wu, X., Zhou, Q., Howard, O. M., Netea, M. G., and Oppenheim, J. J. (2013) TNFR2 is critical for the stabilization of the CD4+ Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J. Immunol. 190, 1076-1084
61. Boden, E. K., and Snapper, S. B. (2008) Regulatory T cells in inflammatory bowel disease. Curr. Opin. Gastroenterol. 24, 733-741
62. Ricciardelli, I., Lindley, K. J., Londei, M., and Quaratino, S. (2008) Antitumour necrosisα therapy increases the number of FOXP3+ regulatoryT cells in children affected by Crohn's disease. Immunology 125, 178-183
63. Ishikawa, D., Okazawa, A., Corridoni, D., Jia, L. G., Wang, X. M., Guanzon, M., Xin, W., Arseneau, K. O., Pizarro, T. T., and Cominelli, F. (2013) Tregs are dysfunctional in vivo in a spontaneous murine model of Crohn's disease. Mucosal Immunol. 6, 267-275
64. Neregård, P., Krishnamurthy, A., Revu, S., Engström, M., af Klint, E., and Catrina, A. I. (2014) Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis. Scand. J. Rheumatol. 43, 85-90
65. Mohler, K. M., Torrance, D. S., Smith, C. A., Goodwin, R. G., Stremler, K. E., Fung, V. P., Madani, H., and Widmer, M. B. (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151, 1548-1561
66. Browning, J. L. (2008) Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol. Rev. 223, 202-220
67. Calmon-Hamaty, F., Combe, B., Hahne, M., and Morel, J. (2011) Lymphotoxin á revisited: general features and implications in rheumatoid arthritis. Arthritis Res. Ther. 13, 232
68. Chiang, E. Y., Kolumam, G. A., Yu, X., Francesco, M., Ivelja, S., Peng, I., Gribling, P., Shu, J., Lee, W. P., Refino, C. J., Balazs, M., Paler-Martinez, A., Nguyen, A., Young, J., Barck, K. H., Carano, R. A., Ferrando, R., Diehl, L., Chatterjea, D., and Grogan, J. L. (2009) Targeted depletion of lymphotoxin-α-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat. Med. 15, 766-773
69. Nielsen, O. H., Vainer, B., Madsen, S. M., Seidelin, J. B., and Heegaard, N. H. (2000) Established and emerging biological activity markers of inflammatory bowel disease. Am. J. Gastroenterol. 95, 359-367
70. Hwang, S. Y., Kim, J. Y., Kim, K. W., Park, M. K., Moon, Y., Kim, W. U., and Kim, H. Y. (2004) IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB- and PI3-kinase/Akt-dependent pathways. Arthritis Res. Ther. 6, R120-R128
71. Emi Aikawa, N., de Carvalho, J. F., Artur Almeida Silva, C., and Bonfá, E. (2010) Immunogenicity of Anti-TNF-κ agents in autoimmune diseases. Clin. Rev. Allergy Immunol. 38, 82-89
72. Panaccione, R., and Ghosh, S. (2010) Optimal use of biologics in the management of Crohn's disease. Therap. Adv. Gastroenterol. 3, 179-189
73. Emery, P. (2012) Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology 51, v22-v30
74. Reinisch, W. (2010) How to manage loss of response to anti-TNF in Crohn's disease? Curr. Drug Targets 11, 152-155
75. Ben-Horin, S., and Chowers, Y. (2014) Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat. Rev. Gastroenterol. Hepatol. 11, 243-255
76. Yarur, A. J., Abreu, M. T., Deshpande, A. R., Kerman, D. H., and Sussman, D. A. (2014) Therapeutic drug monitoring in patients with inflammatory bowel disease. World J. Gastroenterol. 20, 3475-3484
77. Deffar, K., Shi, H. L., Li, L., Wang, X. Z., and Zhu, X. J. (2009) Nanobodies-the new concept in antibody engineering. Afr. J. Biotechnol. 8, 2645-2652
78. Ablynx (2013) Favourable immunogenicity profile of ALX0171, a potent anti-RSV Nanobody, following pulmonary administration. POSTER
79. Almoallim, H., Al-Ghamdi, Y., Almaghrabi, H., and Alyasi, O. (2012) Antitumor necrosis factor-β induced systemic lupus erythematosus. Open Rheumatol. J. 6, 315-319
80. Tack, C. J., Kleijwegt, F. S., Van Riel, P. L., and Roep, B. O. (2009) Development of type 1 diabetes in a patient treated with anti-TNF-κ therapy for active rheumatoid arthritis. Diabetologia 52, 1442-1444
81. Eugster, H. P., Frei, K., Bachmann, R., Bluethmann, H., Lassmann, H., and Fontana, A. (1999) Severity of symptoms and demyelination in MOGinduced EAE depends on TNFR1. Eur. J. Immunol. 29, 626-632
82. Suvannavejh, G. C., Lee, H. O., Padilla, J., Dal Canto, M. C., Barrett, T. A., and Miller, S. D. (2000) Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell. Immunol. 205, 24-33
83. Fischer, R., Maier, O., Siegemund, M., Wajant, H., Scheurich, P., and Pfizenmaier, K. (2011) A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS ONE 6, e27621
84. Kägi, D., Ho, A., Odermatt, B., Zakarian, A., Ohashi, P. S., and Mak, T. W. (1999) TNF receptor 1-dependent βcell toxicity as an effector pathway in autoimmune diabetes. J. Immunol. 162, 4598-4605